You're reading the web version of STAT's popup newsletter, AACR in 30 seconds, your guide to what's happening at the American ...

Daraxonrasib, a pancreatic cancer drug from Revolution Medicines, is showing unprecedented success. For patients like Leanna ...

As one CDC employee, who asked not to be named, put it on Friday, among staff “the general vibe is guarded but hopeful.” ...

When health care infrastructure is attacked and held for ransom by hackers, patients become real casualties,” writes Andrea ...

A few transplant patients in a small study were able to stop using immunosuppressive drugs, thanks to pre-transplant cell ...

Schwartz's background as a physician with plenty of government service experience will likely be popular among lawmakers.

Revolution Medicines announced a stunning survival benefit for its experimental drug in a Phase 3 pancreatic cancer study ...

On Monday, Politico published a poll on vaccine attitudes titled, “More Americans doubt vaccine safety than trust it, ...

Scientists whose work led to powerful obesity drugs like Zepbound are now suggesting targeting the GLP-1 hormone is not ...

New research challenges what we know about GLP-1s, vaccine skepticism, and more health news from Morning Rounds ...

Former Sen. Ben Sasse gives a glimpse of what it's like to be a participant in an tough but promising new drug for pancreatic ...

Scientists are raising a provocative hypothesis about GLP-1 drugs for obesity: Perhaps targeting the GLP-1 hormone isn't ...